When antibiotics are overused, bacteria evolve to survive them, making infections harder and sometimes impossible to treat. This process, called antibiotic resistance, directly caused an estimated 1.27 million deaths worldwide in 2019 and contributed to nearly 5 million more. The consequences reach far beyond resistant superbugs: overuse also damages your body’s own beneficial bacteria, raises your risk of secondary infections, and threatens the safety of routine surgeries and cancer treatments.
How Bacteria Become Resistant
Every time bacteria are exposed to an antibiotic, most die, but a small number with natural genetic variations may survive. Those survivors reproduce, passing their resistance traits to the next generation. This is basic natural selection, but antibiotics accelerate it dramatically. Even very low concentrations of antibiotics, well below what would normally kill bacteria, can select for high-level resistance over successive generations. Low doses can also push bacteria into a “hypermutable” state where their DNA mutates faster than usual, speeding up the development of new defenses.
Bacteria don’t just inherit resistance from their parents. They also share resistance genes sideways, trading genetic material between unrelated species through a process called horizontal gene transfer. When bacteria cluster together in dense communities called biofilms (the slimy layers that form on surfaces like catheters or wounds), this gene-sharing becomes even easier because the cells are packed so closely together. A resistance gene that evolves in one harmless species can quickly end up in a dangerous one.
The genes involved typically fall into a few categories: some change the shape of the target the antibiotic is trying to hit, some pump the drug back out of the cell before it can work, and some produce enzymes that break the antibiotic apart. Bacteria often stack multiple defenses, making them resistant to several drugs at once.
Damage to Your Gut Microbiome
Your digestive tract hosts trillions of beneficial bacteria that help with digestion, immune function, and keeping harmful microbes in check. Antibiotics don’t distinguish between the bacteria causing your infection and the ones keeping you healthy. A single course can cause significant collateral damage, and the recovery timeline is much longer than most people realize.
A 7-day course of clindamycin, a common broad-spectrum antibiotic, sharply reduces populations of key gut bacteria. In one study, those populations remained disrupted for up to two years after treatment ended. Another study found that a 10-day course of ciprofloxacin lowered levels of bifidobacteria (a group important for gut health and immune regulation), while clindamycin for the same duration reduced both bifidobacteria and lactobacilli. The bifidobacteria didn’t return to normal levels until a full year after treatment stopped.
In general, gut bacteria begin returning toward their baseline about a week after antibiotics end, but the recovery is incomplete and unpredictable. Studies tracking patients for up to 12 weeks after treatment consistently find that the microbial community hasn’t fully bounced back, and antibiotic-resistant strains often emerge in the gaps left behind. The more courses you take, the less resilient your microbiome becomes.
Infants are especially vulnerable. Amoxicillin given to infants for just 7 days completely wiped out one important species of bifidobacteria and reduced the overall diversity of that bacterial group. Antibiotics given to mothers during labor to prevent infection also lower bifidobacteria levels in their newborns, potentially affecting immune development during a critical window.
Higher Risk of Secondary Infections
When antibiotics clear out your protective gut bacteria, opportunistic pathogens can move in. The most well-known example is Clostridioides difficile (C. diff), a bacterium that causes severe diarrhea, colon inflammation, and in serious cases, life-threatening complications. C. diff thrives when normal gut flora is depleted.
Antibiotic exposure roughly doubles the risk of developing a C. diff infection, according to a study published in JAMA Network Open. Certain broad-spectrum combinations carry an even higher risk, with some increasing the hazard by more than twofold. People who have never carried C. diff before are particularly susceptible after antibiotic exposure, because they lack even a low-level immune familiarity with the organism.
Antibiotics Prescribed When They Can’t Help
A major driver of overuse is prescribing antibiotics for viral infections, where they have zero effect. Antibiotics kill bacteria; they do nothing against viruses like the flu, common cold, or COVID-19. Yet prescribing rates for viral respiratory infections remain stubbornly high.
More than 50% of patients hospitalized with viral respiratory tract infections receive antibiotics that are likely unnecessary. During the early pandemic, the numbers were even worse: over 80% of hospitalized COVID-19 patients received antibiotics. That rate gradually fell but stabilized around 35% by 2022 to 2023, meaning roughly one in three COVID patients was still getting an antibiotic they almost certainly didn’t need. For non-COVID viral respiratory infections, prescribing in 2023 returned to pre-pandemic patterns of about 50%, which were already too high.
Each unnecessary prescription adds selection pressure for resistant bacteria, both in the patient receiving the drug and in the broader community as resistant strains spread.
Resistant Pathogens Already Here
Antibiotic resistance isn’t a hypothetical future problem. The CDC tracks several resistant pathogens that already cause serious illness in the United States. Among the most concerning are MRSA, which resists the standard antibiotics used for staph infections; vancomycin-resistant Enterococcus (VRE); carbapenem-resistant bacteria that have evolved past one of the last-resort classes of antibiotics; and Candida auris, a fungus resistant to multiple antifungal drugs that spreads easily in healthcare settings.
These organisms are most dangerous in hospitals and long-term care facilities, where patients often have weakened immune systems, open wounds, or medical devices that give bacteria a foothold. But resistant bacteria don’t stay confined to hospitals. They move into communities through discharged patients, contaminated surfaces, and the food supply.
The Livestock Connection
Antibiotic overuse in humans is only part of the picture. Antibiotics have been widely used in livestock, not just to treat sick animals but to promote faster growth. This practice creates resistant bacteria in animals that can then reach people through multiple routes: direct contact with animals, contaminated meat, water runoff from farms, and shared environmental exposure.
Common foodborne bacteria like E. coli, Salmonella, and Campylobacter carry resistance genes that move between livestock, humans, and the environment. The same gene-swapping mechanisms that spread resistance between bacteria in your gut also operate in farm environments, meaning resistance that develops in an animal’s digestive tract can eventually end up in bacteria that infect people. Researchers increasingly view antibiotic resistance as a single interconnected problem spanning human medicine, agriculture, and the environment.
Threats to Surgery and Cancer Treatment
Modern medicine depends on effective antibiotics far beyond treating infections. Joint replacements, organ transplants, cesarean sections, and chemotherapy all rely on antibiotics to prevent or manage the bacterial infections that commonly accompany these procedures. Chemotherapy suppresses the immune system, making patients highly vulnerable to infection; without reliable antibiotics, the risk calculation for many cancer treatments changes dramatically.
Surgical site infections caused by resistant bacteria lead to longer hospital stays, higher complication rates, and increased mortality. As resistance spreads, procedures that are currently routine could become significantly more dangerous. The antibiotics given before surgery to prevent infection only work if the bacteria they’re targeting haven’t already evolved past them.
The Economic Toll
Antibiotic resistance costs the United States an estimated $55 billion annually. About $20 billion of that is direct healthcare spending: longer hospitalizations, more expensive drugs, additional procedures. The remaining $35 billion comes from lost productivity, as patients with resistant infections are sick longer and sometimes permanently disabled. Globally, the economic burden is proportionally larger in countries with fewer healthcare resources and higher rates of unregulated antibiotic use.
These numbers will grow as resistance accelerates. Resistant infections require more intensive treatment, longer recovery periods, and sometimes drugs that cost orders of magnitude more than the standard options they replace. For individual patients, a resistant infection can mean the difference between a short course of oral medication and weeks of intravenous treatment in a hospital.